HC Wainwright Reaffirms Buy Rating for Krystal Biotech (NASDAQ:KRYS)

Krystal Biotech (NASDAQ:KRYS - Get Free Report)'s stock had its "buy" rating reaffirmed by investment analysts at HC Wainwright in a research report issued on Wednesday,Benzinga reports. They currently have a $221.00 target price on the stock. HC Wainwright's price objective would indicate a potential upside of 17.64% from the stock's current price.

A number of other research firms also recently issued reports on KRYS. Chardan Capital reiterated a "buy" rating and issued a $212.00 price objective on shares of Krystal Biotech in a report on Wednesday, December 18th. Citigroup boosted their target price on shares of Krystal Biotech from $204.00 to $206.00 and gave the stock a "neutral" rating in a report on Tuesday, November 5th. One research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company has an average rating of "Buy" and an average target price of $210.00.

Krystal Biotech Trading Up 2.9 %

Shares of NASDAQ KRYS traded up $5.24 during midday trading on Wednesday, reaching $187.86. The company's stock had a trading volume of 293,600 shares, compared to its average volume of 260,850. Krystal Biotech has a fifty-two week low of $107.50 and a fifty-two week high of $219.34. The stock has a market capitalization of $5.40 billion, a price-to-earnings ratio of 62.83 and a beta of 0.84. The stock has a 50 day simple moving average of $157.37 and a 200-day simple moving average of $175.23.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last posted its quarterly earnings data on Monday, February 24th. The company reported $1.52 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.29 by $0.23. Krystal Biotech had a net margin of 30.69% and a return on equity of 11.41%. The company had revenue of $91.10 million for the quarter, compared to the consensus estimate of $91.35 million. During the same period last year, the company earned $0.30 earnings per share. The firm's revenue was up 116.4% compared to the same quarter last year. As a group, equities analysts anticipate that Krystal Biotech will post 6.14 EPS for the current year.

Insider Buying and Selling

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the company's stock in a transaction on Friday, December 13th. The shares were sold at an average price of $164.78, for a total value of $4,119,500.00. Following the transaction, the insider now directly owns 1,475,882 shares in the company, valued at $243,195,835.96. The trade was a 1.67 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 14.10% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Krystal Biotech

Several institutional investors and hedge funds have recently modified their holdings of the stock. FMR LLC increased its holdings in shares of Krystal Biotech by 0.5% in the fourth quarter. FMR LLC now owns 4,314,014 shares of the company's stock valued at $675,833,000 after purchasing an additional 21,133 shares during the last quarter. Vanguard Group Inc. increased its holdings in shares of Krystal Biotech by 1.0% in the fourth quarter. Vanguard Group Inc. now owns 2,878,451 shares of the company's stock valued at $450,938,000 after purchasing an additional 28,707 shares during the last quarter. Avoro Capital Advisors LLC increased its holdings in shares of Krystal Biotech by 0.3% in the fourth quarter. Avoro Capital Advisors LLC now owns 2,628,822 shares of the company's stock valued at $411,831,000 after purchasing an additional 6,600 shares during the last quarter. State Street Corp increased its holdings in shares of Krystal Biotech by 9.0% in the third quarter. State Street Corp now owns 1,452,811 shares of the company's stock valued at $264,455,000 after purchasing an additional 119,936 shares during the last quarter. Finally, Geode Capital Management LLC increased its holdings in shares of Krystal Biotech by 2.0% in the third quarter. Geode Capital Management LLC now owns 591,631 shares of the company's stock valued at $107,714,000 after purchasing an additional 11,411 shares during the last quarter. 86.29% of the stock is currently owned by institutional investors and hedge funds.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).